Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRx Pharmaceuticals, Inc. reports clinical, regulatory, manufacturing, and subsidiary developments for a biopharmaceutical business focused on neuroplastic therapies for depression, PTSD, suicidality, and related conditions. Company updates center on NRX-100 preservative-free ketamine, NRX-101 as a D-cycloserine/lurasidone fixed-dose combination, FDA communications, generic-drug and new-drug application pathways, and clinical work involving treatment-resistant depression and suicidality.
Recurring news also covers commercial manufacturing preparations, drug-shortage context for ketamine injection, robotic-enabled transcranial magnetic stimulation initiatives through NRx Defense Systems, and interventional psychiatry activity through HOPE Therapeutics. Additional company developments include partnerships involving digital monitoring tools, leadership appointments, and research programs serving military, first-responder, and broader behavioral-health settings.
NRx Pharmaceuticals (Nasdaq: NRXP) will host a conference call and Q&A on Monday, August 10, 2026 at 8:30 a.m. ET to discuss the FDA’s completion of first-cycle review of its ANDA for preservative-free ketamine. CEO Jonathan Javitt, Chief Commercial Officer Glenn Tyson, and Director Chaim Hurvitz will participate. Investors can join via live webcast on the company’s investor relations site or by domestic and international dial-in, with a replay available. NRx is a clinical-stage biopharmaceutical company developing NRX-100 (preservative-free IV ketamine) and NRX-101, both holding FDA Fast Track or Breakthrough Therapy designations for suicidal depression.
NRx Pharmaceuticals (Nasdaq: NRXP) reported that the FDA has completed first-cycle review of its ANDA for preservative-free intravenous ketamine with no major deficiencies related to the drug product, ingredients, proposed labeling, CMC, or other drug-related review matters, and is not requiring new clinical, safety, or efficacy data.
The only remaining item is a packaging-related Major Deficiency: FDA requested manufacturer certification that the luer lock vial tip, already used in three approved ANDA products with 11.9 million complaint-free doses shipped in 12 months, is produced on the same lines and methods. NRx is submitting this attestation, and FDA committed to review it in the shortest possible cycle. NRx views this first-cycle outcome, achieved in a context where only 14–18% of ANDAs are typically approved in first cycle, as a key milestone that de-risks its path to potential approval and commercialization. The company will host a webcast on August 10, 2026 to discuss the update.
Summary not available.
NRx Pharmaceuticals (Nasdaq: NRXP) reported that subsidiary HOPE Therapeutics has treated its first patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System at clinics in West Palm Beach and Sarasota, Florida.
The AI-guided, sub-millimetric navigation is integrated into outpatient TMS workflows and supports NRx's planned SPARC-TMS trial of NRX-101 with robotic-enabled TMS for depression and suicidality.
Summary not available.
ZETA SURGICAL and HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), reported the first patient treated with the FDA-cleared Zeta TMS Navigation System at a Sarasota clinic on June 23, 2026.
Systems are installed in Sarasota and West Palm Beach, using AI-based RealTrack™ image guidance for sub-millimetric TMS targeting in treatment-resistant depression and other neuropsychiatric conditions.
NRx Pharmaceuticals (Nasdaq: NRXP) received FDA authorization for an Intermediate Population Expanded Access Protocol for NRX-101, a fixed-dose combination of D-cycloserine and lurasidone, to augment accelerated Transcranial Magnetic Stimulation (TMS) in Treatment-Resistant Depression.
The company has also initiated the pivotal SPARC-TMS trial in civilian and military settings and will initially provide NRX-101 under expanded access at no cost other than shipping and FDA-required data collection.
NRx Pharmaceuticals (Nasdaq: NRXP)/b) highlighted a peer-reviewed poster presented at the 2026 American Society of Clinical Psychopharmacology conference. The Osmind/Yale study used Real World Evidence from 8,224 IV ketamine and 1,830 intranasal esketamine patients with treatment-resistant depression.IV ketamine showed higher remission (34% vs 26%) and response (63% vs 58%) rates, with odds ratios of 1.51 for remission and 1.22 for response. Authors stressed key limitations, including non-randomized treatment assignment and data drawn only from clinics using Osmind’s electronic medical record system.
NRx Pharmaceuticals (Nasdaq: NRXP) closed a public offering of common stock at $3.50 per share, raising approximately $22.3 million in gross proceeds, including the underwriters’ option. The company plans to use net proceeds for working capital and general corporate purposes to support growth.
NRx Pharmaceuticals (Nasdaq: NRXP) priced an underwritten public offering of 5,714,286 common shares at $3.50 per share, targeting approximately $20.0 million in gross proceeds, or $23.0 million if the underwriters’ 30-day option for 857,142 additional shares is fully exercised.
The offering is expected to close on June 4, 2026, subject to customary conditions. Net proceeds are intended for working capital and general corporate purposes to support growth. The deal uses an effective Form S-3 shelf registration statement, with BTIG and Lucid Capital Markets as bookrunning managers.